Over 100 years serving the Lord home and around the world
First Baptist Church
We are a church who's members come from many nations of origin to worship together!

From December 25 and has moved its decision day.

Bristol-Myers extends period to review BLA for ipilimumab in melanoma Bristol-Myers Squibb Business today announced that the U.S. Food and Drug Administration has motivated that additional time must complete the overview of the biologics permit program for ipilimumab in pre-treated advanced melanoma, from December 25 and has moved its decision day, 2010 to March 26, 2011. Related StoriesOncolytic viral therapy accepted in the U.S. For make use of against late-stage melanomaDiscovery may open new doors to understanding how melanoma grows and spreadsStudy talks about survival benefits of medical resection for melanoma sufferers with abdominal metastasesIn response to an FDA request, Bristol-Myers Squibb submitted further evaluation of data pertaining to the existing application for pre-treated advanced melanoma and the agency considers this to be a main amendment to the drug’s BLA.Because of its part, Alameda County provides settled on a decidedly stripped-down message, launching an advertisement marketing campaign this week that has scantily clad family members holding strategically placed indications that read: Cover YOUR LOVED ONES . Butler is merely among the many advocates worried about how youth of all incomes levels and ethnicities are going to fare after the Affordable Care Action is applied. She directs the California branch of the Young Invincibles, an organization focused on advancing and informing healthcare options for young adults aged 18 to 34.